Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?

Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and combat...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtin, Nicola, Bányai, Krisztián, Thaventhiran, James, Le Quesne, John, Helyes, Zsuzsanna, Bai, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280733/
https://www.ncbi.nlm.nih.gov/pubmed/32441764
http://dx.doi.org/10.1111/bph.15137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280733/
https://www.ncbi.nlm.nih.gov/pubmed/32441764
http://dx.doi.org/10.1111/bph.15137

Ejemplares similares